In addition, treatment of MSCs with anti-IFN-β-treated Tr1 cells significantly increased the clinical arthritis score and incidence of arthritis compared with MSC and Tr1 cell therapy (data not shown), suggesting that IFN-β plays an important role in IDO induction in MSCs. Here, IDO1 is linked to arthritic joint disease.